Skip to content

Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT)

Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01219231
Enrollment
46
Registered
2010-10-13
Start date
2010-08-31
Completion date
2015-01-31
Last updated
2016-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose Tolerance

Keywords

Exercise, elderly, cognition, prevention, cognitive decline, Lifestyle

Brief summary

The researchers will investigate whether exercise could provide positive effects on general brain functions in elderly people with impaired glucose tolerance.

Detailed description

The age-related degradation of cognitive functions even to the point of neurodegenerative disorders such as Alzheimer's disease are a growing public-health concern with devastating effects. Referring to animal data, empirical studies, and pilot human trials, exercise should improve cognitive functions such as learning and memory. To test this hypothesis, the researchers study general brain functions in elderly subjects (50-80 years old) with impaired glucose tolerance during a short term exercise program.

Interventions

BEHAVIORALExercise

6 months of aerobic exercise

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* subjects with impaired glucose tolerance * 50-65 years old * moderate to heavy weight (BMI 25-35) * must be able to do exercise intervention

Exclusion criteria

* diabetes * younger than 50 years * BMI \< 25 * psychiatric medication * severe disease * MMSE \< 26 * severe cardiovascular disorders

Design outcomes

Primary

MeasureTime frame
Auditory Verbal Learning TaskPrior to intervention and after 6 months of intervention

Secondary

MeasureTime frame
Functional/Structural brain changesPrior to intervention and after 6 months of intervention
Plasma biomarkersPrior to intervention and after 6 months of intervention

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026